Literature DB >> 10421247

Adherence to guidelines for antiretroviral therapy and for preventing opportunistic infections in HIV-infected adults and adolescents in Ryan White-funded facilities in the United States.

J E Kaplan1, D L Parham, L Soto-Torres, K van Dyck, J A Greaves, K Rauch, B Ellis, H E Amandus.   

Abstract

To determine adherence by health care providers to guidelines for antiretroviral therapy and for prevention of opportunistic infections (OIs) in adults with HIV infection in federally funded facilities in the United States, we reviewed records of HIV-infected adults (>13 years) in 11 Ryan White Title III facilities in four states for information on eight standard-of-care recommendations during November 1996 through September 1997. Eligibility required a visit to the facility within 6 months before record abstraction and a lowest CD4+ lymphocyte count <500 cells/microl. Reviews were completed for 148 patients in Maryland, 355 in New York, 370 in Georgia, and 538 in Illinois. Adherence to prevention measures by health care providers was >85% for HIV plasma RNA testing, prescription of antiretroviral therapy, Pneumocystis carinii pneumonia (PCP) prophylaxis, anti-Toxoplasma antibody testing, and obtaining Papanicolaou (Pap) smears but lower (69%-80%) for Mycobacterium avium complex (MAC) prophylaxis, tuberculin skin testing (TST), and pneumococcal vaccination. Adherence was similar by patient age, gender, racial/ethnic group, urban versus rural, and hospital versus clinic setting but was generally lower for injecting drug users (IDUs) than for patients with other HIV exposures (p < .05 by multivariate analysis for TST, anti-Toxoplasma antibody testing, Pap smear, and measurement of HIV plasma RNA). Adherence by health care providers to guidelines for preventing OIs in these federally funded facilities is generally high but could be improved for some prevention measures, for instance, MAC prophylaxis, TST, and pneumococcal vaccination, especially for IDUs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10421247     DOI: 10.1097/00126334-199907010-00008

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  8 in total

1.  Use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors among Medicaid beneficiaries with AIDS.

Authors:  U Sambamoorthi; P J Moynihan; E McSpiritt; S Crystal
Journal:  Am J Public Health       Date:  2001-09       Impact factor: 9.308

Review 2.  Practice guidelines and measurement: state-of-the-science.

Authors:  Patricia C Dykes
Journal:  Nurs Outlook       Date:  2003 Mar-Apr       Impact factor: 3.250

3.  Frequency of cervical cancer and breast cancer screening in HIV-infected women in a county-based HIV clinic in the Western United States.

Authors:  Lisa Rahangdale; Clea Sarnquist; Azita Yavari; Paul Blumenthal; Dennis Israelski
Journal:  J Womens Health (Larchmt)       Date:  2010-04       Impact factor: 2.681

4.  Cervical cancer screening among HIV-positive women. Retrospective cohort study from a tertiary care HIV clinic.

Authors:  Pamela Leece; Claire Kendall; Claire Touchie; Kevin Pottie; Jonathan B Angel; James Jaffey
Journal:  Can Fam Physician       Date:  2010-12       Impact factor: 3.275

5.  Number of Primary Care Visits Associated with Screening for Cervical Dysplasia among Women with HIV Infection in Harris County, Texas, United States of America.

Authors:  Natalie Jm Dailey Garnes; Gypsyamber D'Souza; Elizabeth Chiao
Journal:  HIV Adv Res Dev       Date:  2015-02-16

6.  Physician specialization and women's primary care services in an urban HIV clinic.

Authors:  John R Koethe; Richard D Moore; Krystn R Wagner
Journal:  AIDS Patient Care STDS       Date:  2008-05       Impact factor: 5.078

7.  Population pharmacokinetic modeling and simulations of berotralstat for prophylactic treatment of attacks of hereditary angioedema.

Authors:  Amanda Mathis; Mark Sale; Melanie Cornpropst; William P Sheridan; Shu Chin Ma
Journal:  Clin Transl Sci       Date:  2022-02-25       Impact factor: 4.438

8.  Nonadherence to primary prophylaxis against Pneumocystis jirovecii pneumonia.

Authors:  James D Heffelfinger; Andrew C Voetsch; Glenn V Nakamura; Patrick S Sullivan; A D McNaghten; Laurence Huang
Journal:  PLoS One       Date:  2009-03-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.